Format

Send to

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2005 Feb;52(2):240-6.

Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.

Author information

1
Probity Medical Research, Hannover Medical University, Waterloo, Ontario, Canada. kapapp@probitymedical.com

Abstract

OBJECTIVE AND METHODS:

The safety and efficacy of treatment with pimecrolimus cream 1% was evaluated for up to 2 years in infants and young children with atopic dermatitis. Ninety-one patients participated in a 1-year, open-label extension to a 1-year double-blind study. Of these, 76 received pimecrolimus for 2 years. Pimecrolimus was applied twice daily at the first signs or symptoms of the disease until clearance. Outcome measures included the incidence of adverse events and the Eczema Area and Severity Index (EASI).

RESULTS:

No patient discontinued because of adverse events. The incidence of systemic and skin infections did not increase over time. Over the 2-year period, 2 patients experienced an episode of clinically diagnosed eczema herpeticum. In patients receiving pimecrolimus for 2 years, the mean decrease in EASI score from baseline was 68.7% at 3 months and 70.8% at 24 months.

CONCLUSION:

Treatment with pimecrolimus cream 1% for up to 2 years was well tolerated and resulted in a marked and sustained improvement of atopic dermatitis.

PMID:
15692468
DOI:
10.1016/j.jaad.2004.09.016
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center